Trial
NCT02908165
Randomized Phase II Trial of Chemoembolization and Sorafenib
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Yale University
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
conventional TACE in combination with sorafenib, administered on a continuous schedule
Why stopped
A future study will be taking place using the same patient population.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-10